Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03515629
Title REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Cemiplimab + Ipilimumab

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST